<DOC>
	<DOCNO>NCT00652444</DOCNO>
	<brief_summary>The primary outcome percentage reduction LDL-C 6 week randomization .</brief_summary>
	<brief_title>Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population : A Prospective , Multicentre , Randomized , Double-Blind , Placebo-Controlled Trial ( 0653-151 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Patients know Coronary Artery Disease ( CAD ) primary hypercholesterolemia , treat simvastatin 20mg . Simvastatin consumption meant subject must currently take simvastatin 20mg daily , history take least 80 % daily evening dos precede 6 week prior baseline visit Age least 18 year 75 year less Calculated LDLC concentration least 2.6 4.1mmol/l less use Friedewald equation , triglyceride less 3.99 mmol/l Congestive heart failure ( defined New York Heart Association class III IV heart failure ) Uncontrolled cardiac arrhythmia Acute coronary syndrome , coronary bypass surgery coronary angioplasty within 3 month study entry History unstable severe peripheral artery disease within 3 month study entry Uncontrolled hypertension study entry Uncontrolled newly diagnose diabetes mellitus ( within 3 month study entry ) Uncontrolled endocrine metabolic disease know influence serum lipid lipoproteins ; know impairment renal function Active chronic hepatic hepatobiliary disease Disorders would limit study evaluation participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>